timothy sykes logo
Ovid Therapeutics Surge: Positive Phase 1 Data Ignites Market Confidence Thumbnail
ADD US ONG Google News

Ovid Therapeutics Surge: Positive Phase 1 Data Ignites Market Confidence

TIM SYKES•UPDATED APR. 9, 2026, 11:32 AM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

Ovid Therapeutics Inc.’s stocks have been trading up by 13.46 percent after promising preclinical Alzheimer’s data boosts investor optimism.

Candlestick Chart

Live Update At 11:32:00 EDT: On Thursday, April 09, 2026 Ovid Therapeutics Inc. stock [NASDAQ: OVID] is trending up by 13.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Ovid Therapeutics has experienced a financial turnaround, with its recent earnings report defying Wall Street predictions. In the most recent quarter, Ovid reported a positive EPS of $0.06 per share against expectations of a $(0.10) loss per share. Despite modest total revenue of $718,000, this marks a substantial leap from what analysts anticipated, underlining the company’s strategic focus on cost management and effective R&D investments.

Key metrics show strong financial health, such as a cash balance over $90M, providing a cash runway through late 2028. With favorable gross margins and a high current ratio of 9, the company is well-positioned financially. Nevertheless, the high price-to-sales ratio at nearly 47 highlights some concerns over valuation, requiring careful navigation in upcoming quarters.

Examining Ovid’s stock trends over recent weeks, a consistent upward trajectory becomes apparent. With a closing price that moved from $2.10 to $2.95 within a span of days, the bullish sentiment aligns with promising clinical updates and strategic funding injections.

Strategic Moves and Market Reactions

The biotech firm recently saw its stock rise sharply due to several significant developments. The successful Phase 1 trial results of OV329 have emphasized favorable safety and efficacy data, leading to an expansion plan into seizure treatments beyond focal onset seizures. This promising progress adds fuel to Ovid’s growth story, as it seeks to penetrate untapped segments like tuberous sclerosis complex seizures.

Importantly, the company secured $60M through a PIPE financing deal, led by key biotech investors, reinforcing its plans to amplify OV329’s development scope. Analysts responded positively, with Wedbush raising the firm’s price target and reinforcing an Outperform rating. Roth Capital followed suit by advising a Buy recommendation, improving their valuation forecasts based on data-driven confidence.

The company’s solid balance sheet and progressive R&D have attracted noteworthy attention, establishing Ovid as a strong contender in the biotech landscape. By leveraging strategically-allocated funds coupled with favorable trial outcomes, Ovid is poised to accelerate its advancements and capture substantial market share.

More Breaking News

Conclusion

The series of strategic endeavours by Ovid Therapeutics paints an optimistic picture for the company’s future. As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This approach is reflective of Ovid’s own methodical progress. With financial stability supported by trader confidence, and compelling clinical data backing their pharmaceutical advances, Ovid is confidently poised for growth. This upward momentum is a testimony to the company’s well-crafted strategy and promising scientific endeavors that appeal to traders and market watchers alike. While challenges may arise, the strong foundation and ambitious outlook suggest an exciting trajectory ahead.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading OVID

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”